<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441398</url>
  </required_header>
  <id_info>
    <org_study_id>NITFQM0720OR</org_study_id>
    <nct_id>NCT04441398</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients</brief_title>
  <official_title>Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita -RJ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Farmoquimica S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to demonstrate a decrease in complications among ambulatory patients who are
      diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of
      standard care compared to patients who receive standard care and placebo only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim is to demonstrate a decrease in complications among ambulatory patients who are
      diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of
      standard care compared to patients who receive standard care and placebo only.

      After 7 days of treatment, the Investigator can extend the treatment duration for another 7
      days at his/her discretion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive either nitazoxanide (n=150) or placebo (n=150)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in signs and symptoms scale</measure>
    <time_frame>21 days</time_frame>
    <description>Symptoms will be assessed using a 5 point scale (1- excellent, 2- good, 3- fair, 4 - poor 5 - very poor).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>21 days</time_frame>
    <description>Number of participants with treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects hospitalized after start of treatment and before the end of the study</measure>
    <time_frame>21 days</time_frame>
    <description>Change in clinical condition - WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects that need mechanical ventilation after start of treatment and before the end of the study</measure>
    <time_frame>21 days</time_frame>
    <description>Change in clinical condition - WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms</measure>
    <time_frame>21 days</time_frame>
    <description>Time required (days) to full symptom recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mortality within 21-days</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluation of change in acute respiratory syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>covid19</condition>
  <arm_group>
    <arm_group_label>nitazoxanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive nitazonanide 600 mg TID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo TID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.</description>
    <arm_group_label>nitazoxanide</arm_group_label>
    <other_name>Viranitta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent from patient or legal representative.

          -  Subject of both genders (male and female not pregnant and not breastfeeding) aged over
             49;

          -  Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase
             chain reaction (RT-PCR) from any diagnostic sampling source;

          -  Symptomatic subject with symptoms for up to 72 hours who does not require
             hospitalization, with signs and symptoms of acute respiratory viral infection
             characterized by a feverish sensation or fever, which may or may not be present at the
             time of the examination (which may be reported to the health professional),
             accompanied by cough or sore throat or runny nose or difficulty breathing and:

             i) Oxygen saturation â‰¥ 90%; ii) Risk classification for COVID-19 between low (A) or
             medium (B) (scores 1 to 19), according to the Brazilian Ministry of Health.

        Exclusion Criteria:

          -  Participating in another RCT in the past 12 months;

          -  Presence of comorbidities, which have a contraindication to the use of the study
             product, not being restricted to:

               -  HIV or HTLV virus infection;

               -  Chronic hepatitis C (HCV) treated with direct antiviral drugs;

               -  Liver failure;

               -  Severe renal failure, including dialysis;

          -  Present hypersensitivity to the study product (nitazoxanide), as well as to related
             compounds;

          -  Concomitant administration of drugs that may interact with the product under study
             (nitazoxanide);

          -  Participants who underwent treatment with other antiviral drugs;

          -  Subject in antineoplastic treatment with chemotherapy or radiation therapy;

          -  Subject with severe autoimmune diseases in immunosuppression;

          -  Transplanted participants;

          -  Pregnant or lactating women;

          -  Any other clinical condition that is deemed by the Investigator to be an imminent risk
             to the health and life of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edimilson Migowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NEPS SEMUS Mesquita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thiago Wendel, MD</last_name>
    <phone>+55 21 99309-9668</phone>
    <email>thiagowendel83@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luciana Ferrara</last_name>
    <phone>+55 19 981428814</phone>
    <email>luciana.ferrara@azidusbrasil.com.br</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

